10-Q: Catheter Precision Reports Wider Losses Amid Strategic Acquisitions

Catheter Precision, Inc. reported increased net losses and negative cash flows for the first half of 2025, despite strategic acquisitions and capital raising efforts, raising substantial doubt about its ability to continue as a going concern.

Summary

• Catheter Precision, Inc. (VTAK) reported a net loss of $9.5 million for the six months ended June 30, 2025, an increase from $6.9 million in the prior year period.
• Cash and cash equivalents decreased to $0.8 million as of June 30, 2025, from $2.9 million at December 31, 2024, with $4.6 million used in operating activities.
• The company acquired assets related to the Cardiac Pulmonary Nerve Stimulation (CPNS) System from Cardionomic, Inc. for $1.9 million, expensed as acquired in-process research and development.
• A new subsidiary, KardioNav, Inc., was formed to develop electrophysiology mapping technologies, integrating VIVO System IP with third-party patents.
• The company completed a May 2025 PIPE Financing, raising $1.5 million in cash and $0.9 million in trading debt securities, and an At-the-Market (ATM) Offering, selling 4,183,589 common shares for $1.7 million gross proceeds.
• Revenues increased to $355 thousand for the six months ended June 30, 2025, up from $175 thousand in the prior year, driven by a $230 thousand increase in LockeT sales, partially offset by a $50 thousand decrease in VIVO System sales.
• Selling, general and administrative expenses increased by $1.0 million, primarily due to higher salaries and benefits from increased headcount and stock-based compensation.
• A 1-for-19 reverse stock split was approved on July 25, 2025, effective August 15, 2025, reducing outstanding common shares from approximately 18.86 million to 0.99 million.
• The company identified material weaknesses in internal control over financial reporting, including lack of segregation of duties and insufficient review controls for financial reporting and third-party valuations.

Sentiment

Score: 3

Explanation: The company is actively pursuing strategic acquisitions and capital raises, which are positive for long-term growth potential. However, the significant increase in net losses, accelerated cash burn, and explicit 'going concern' warning indicate severe short-term financial distress and high operational risk, outweighing the strategic positives.

Positives

• Total revenues increased by $180 thousand for the six months ended June 30, 2025, compared to the prior year, primarily driven by a $230 thousand increase in LockeT device sales.
• Successfully raised $1.5 million in cash and acquired $0.9 million in trading debt securities through the May 2025 PIPE Financing.
• Sold 4,183,589 common shares for $1.7 million gross proceeds through the At-the-Market (ATM) Offering, demonstrating continued access to capital markets.
• Acquired the Cardiac Pulmonary Nerve Stimulation (CPNS) System, a novel technology for late-stage heart failure treatment, expanding the product pipeline.
• Formed KardioNav, Inc. to advance electrophysiology mapping technologies, integrating existing VIVO IP with new third-party patents, indicating future innovation efforts.
• A US patent for the LockeT device was granted in April 2025, which triggers an additional royalty stream for the inventor and validates the product's intellectual property.

Negatives

• Net loss increased to $9.5 million for the six months ended June 30, 2025, compared to $6.9 million in the prior year period.
• Cash and cash equivalents significantly decreased to $0.8 million as of June 30, 2025, from $2.9 million at December 31, 2024.
• Net cash used in operating activities increased to $4.6 million for the six months ended June 30, 2025, from $3.6 million in the prior year, indicating increased cash burn.
• Accumulated deficit grew to $301.5 million as of June 30, 2025, reflecting continued historical losses.
• The company has a working capital deficit of $2.6 million as of June 30, 2025.
• VIVO System sales decreased by $50 thousand due to reduced sales efforts, changes in commercial leadership, and a key EU-based sales consultant's prolonged medical leave.
• Substantial doubt exists about the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• Material weaknesses in internal control over financial reporting were identified, including lack of segregation of duties and insufficient review controls for financial reporting and third-party valuations.

Risks

• Inability to develop assets acquired by KardioNav and Cardionomix without additional financing, which may not be available on acceptable terms or at all.
• Anticipated clinical trials may not yield expected results, or future trials may be more costly or delayed.
• Requirement to raise additional funds to finance operations and continue as a going concern, with no guarantee of securing such financing in a timely manner or on favorable terms.
• Issuance of equity securities to raise funds may dilute existing stockholders, and new securities may have senior rights.
• History of losses and expectation of continued losses, with no assurance of achieving profitability.
• Ability to increase At-the-Market offering availability is subject to necessary approvals, certifications, legal opinions, and accounting comfort letters, with no guarantee of success.
• Identified material weaknesses in internal control over financial reporting could adversely affect the ability to report financial results accurately and timely.
• Compliance with Sarbanes-Oxley Act Section 404 could have a material adverse impact on the business.
• Dependence on obtaining components in sufficient quantities on commercially reasonable terms, with risk of supplier failure or inability to manage components effectively.
• Risk that hospitals, physicians, and patients may not accept current and future products, or that the market for product indications is smaller than expected.
• Adverse effects from product liability claims, unfavorable court decisions, or legal settlements.
• Limitations on the ability to use net operating loss carryforwards.
• Subject to pervasive and continuing regulation by the FDA and other regulatory agencies, with risks of denied or delayed product clearances and extensive regulatory scrutiny post-clearance.
• Products may be subject to recalls, revocations, or suspensions after regulatory approval, diverting resources and harming reputation.
• Changes in trade policies, including new or higher tariffs, could pressure average selling prices and adversely affect revenues and operating results.

Future Outlook

Management expects operating losses and negative cash flows to continue for the foreseeable future and needs to raise additional capital to fund research, development, and commercial operations. The company plans to raise additional capital through public or private equity or debt financing, including continuing its At-the-Market (ATM) offering, to meet operating and capital requirements for at least 12 months. Cardionomix plans to complete pivotal clinical trials and obtain necessary regulatory approvals for the CPNS System. KardioNav intends to integrate VIVO mapping intellectual property with Chelak's patents to develop a new system, with research and development activities in the planning phase. The company is assessing the potential impact of the recently enacted U.S. tax legislation (OBBBA) on its future financial position, results of operations, and cash flows.

Management Comments

• Management expects operating losses and negative cash flows to continue for the foreseeable future, and the Company needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its research, development, and commercial operations.
• Management estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed consolidated financial statements.
• The Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders.
• If we are unable to do so, we will be required to reduce our spending rate to align with expected revenue levels and cash reserves, although there can be no guarantee that we will be successful in doing so. If we are unable to do so, we will be required to suspend a portion or all of our operations and/or potentially seek relief from our creditors.
• We have identified material weaknesses in our internal control over financial reporting and these material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.

Industry Context

The company operates in the cardiac electrophysiology (EP) field, a specialized segment of the medical device industry focused on diagnosing and treating heart rhythm disorders. Its strategy involves developing novel technologies like the VIVO System and LockeT, and expanding its pipeline through acquisitions such as the CPNS System and the formation of KardioNav. This indicates a focus on innovation and market expansion within a highly competitive industry. The company's reliance on external financing for R&D and commercialization is typical for early to mid-stage medical device companies developing new technologies that require significant upfront investment and regulatory approvals before generating substantial revenue.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. Therefore, a direct comparison to industry standards is not possible based on the provided information.
• The company's recurring net losses and negative cash flows are common for medical device companies in the development and early commercialization phases, as significant capital is required for R&D, clinical trials, regulatory approvals, and market penetration before achieving profitability.
• The substantial doubt about going concern indicates a higher financial risk compared to more established, profitable industry players, but is not uncommon for companies at this stage of development that are heavily reliant on external funding.

Management Changes

Corporate Governance

Related Party Transactions

• David A. Jenkins (Executive Chairman and CEO) and his affiliates hold significant Series X Convertible Preferred Stock and are beneficiaries of LockeT royalty rights (11.82% of net sales).
• Related Party Notes: The company owes $1.5 million in principal and $151 thousand in accrued interest as of June 30, 2025, to David A. Jenkins, entities controlled by him (FatBoy Capital), and the Jenkins Family Charitable Institute. These notes mature on January 31, 2026, with a 12% annual interest rate after August 31, 2024.
• KardioNav Promissory Notes: On July 11, 2025, KardioNav issued two short-term promissory notes totaling $300 thousand to the Company's CEO and Lifestim, Inc. (a company controlled by the CEO), with a maturity date of July 11, 2026, and 4.2% interest.
• Cardionomix Ownership: The company owns 82% of Cardionomix, while the CEO and his affiliates own 12% of the common stock.
• KardioNav Ownership: The company owns 57% of KardioNav, while the CEO and his affiliates own 10% of the common stock.
• LockeT Royalty to Inventor: An additional 2% royalty on LockeT net sales (after initial $1M paid, up to $10M total) is payable to Auston Locke, son of Robert Locke (VP of Product Development).

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and future equity capital raises. The 1-for-19 reverse stock split will reduce the number of outstanding shares, potentially increasing per-share price but not changing overall equity value. The 'going concern' warning indicates high investment risk.
• Employees: Increased headcount and new hires, including a CFO, suggest some growth in opportunities, but the overall financial instability could pose job security concerns.
• Customers: Continued development of VIVO, LockeT, CPNS, and KardioNav technologies aims to provide novel medical solutions, potentially improving patient outcomes and procedural efficiency.
• Creditors: The company's 'going concern' warning and reliance on future financing pose risks to creditors, particularly those with short-term notes payable. Claims against subsidiaries like Cardionomix and KardioNav are limited to their respective assets.
• Suppliers: The company's financial instability and need for ongoing capital raises could impact its ability to meet payment obligations to suppliers, though no specific supplier concentration risk is highlighted as critical.

Next Steps

• Cardionomix plans to complete the pivotal clinical trial and obtain necessary regulatory approvals from the FDA for the CPNS System.
• KardioNav intends to integrate VIVO mapping intellectual property with Chelak's assigned patents to develop a new system, with research and development activities in the planning phase.
• Management plans to raise additional capital through public or private equity or debt financing to fund operations and pay debts for at least the next 12 months.
• The company will continue to assess the potential impact of the One Big Beautiful Bill (OBBBA) tax legislation on its future financial position, results of operations, and cash flows.
• Management is developing a remediation plan for identified material weaknesses in internal control over financial reporting, including expanding accounting and financial reporting teams and establishing new review policies.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, evidenced by a substantial increase in net losses, accelerated cash burn, and an explicit 'going concern' warning. While strategic acquisitions and capital raises are underway, they have not stemmed the losses or alleviated the liquidity crisis. The identified material weaknesses in internal controls further compound the risk. The upcoming 1-for-19 reverse stock split is often a sign of a company struggling to maintain its stock price and exchange listing, and it does not fundamentally improve the company's financial health. Given the high operational risk, significant accumulated deficit, and ongoing reliance on dilutive financing with no clear path to profitability, a seasoned investor would likely view this as a 'strong sell' due to the high probability of further value erosion.

Keywords

Cardiac Electrophysiology, Medical Devices, VIVO System, LockeT Device, CPNS System, KardioNav, Asset Acquisition, SEC Filing, 10-Q, Going Concern, Capital Raise, Biotechnology, Healthcare Technology, Patent, Promissory Note, Warrants, Clinical Trials, FDA Approval